Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Affiliations

¹ Ramon y Cajal University Hospital, Madrid, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² University of California, San Francisco, CA, USA.
³ Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium.
⁴ Leeds Institute of Cancer and Pathology and St James's University Hospital, Leeds, UK.
⁵ Mayo Clinic, Jacksonville, FL, USA.
⁶ Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
⁷ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁸ The West Clinic, Memphis, TN, USA.
⁹ Institut Curie, Paris, France.
¹⁰ Sarah Cannon Research Institute, Nashville, TN, USA.
¹¹ Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹² Centre Oscar Lambret, Lille, France.
¹³ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
¹⁴ Nektar Therapeutics, San Francisco, CA, USA.
¹⁵ Consultant, Sebastopol, CA, USA.
¹⁶ Texas Oncology-Baylor Charles A. Sammons Cancer Center/U.S. Oncology, 3410 Worth Street, Suite 400, Dallas, TX, 75246, USA. joyce.oshaughnessy@usoncology.com.

Published Erratum

Javier Cortés et al. Breast Cancer Res Treat. 2017 Nov.

. 2017 Nov;166(1):327-328.

doi: 10.1007/s10549-017-4482-3.

¹ Ramon y Cajal University Hospital, Madrid, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
² University of California, San Francisco, CA, USA.
³ Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium.
⁴ Leeds Institute of Cancer and Pathology and St James's University Hospital, Leeds, UK.
⁵ Mayo Clinic, Jacksonville, FL, USA.
⁶ Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
⁷ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁸ The West Clinic, Memphis, TN, USA.
⁹ Institut Curie, Paris, France.
¹⁰ Sarah Cannon Research Institute, Nashville, TN, USA.
¹¹ Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹² Centre Oscar Lambret, Lille, France.
¹³ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
¹⁴ Nektar Therapeutics, San Francisco, CA, USA.
¹⁵ Consultant, Sebastopol, CA, USA.
¹⁶ Texas Oncology-Baylor Charles A. Sammons Cancer Center/U.S. Oncology, 3410 Worth Street, Suite 400, Dallas, TX, 75246, USA. joyce.oshaughnessy@usoncology.com.

No abstract available

Figures

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. Cortés J, et al. Breast Cancer Res Treat. 2017 Sep;165(2):329-341. doi: 10.1007/s10549-017-4304-7. Epub 2017 Jun 13. Breast Cancer Res Treat. 2017. PMID: 28612225 Free PMC article.